Vaxcyte (PCVX) Competitors

Vaxcyte has higher earnings, but lower revenue than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

In the previous week, Revolution Medicines had 14 more articles in the media than Vaxcyte. MarketBeat recorded 24 mentions for Revolution Medicines and 10 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.46 beat Revolution Medicines' score of 0.43 indicating that Vaxcyte is being referred to more favorably in the media.

Vaxcyte has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.

Vaxcyte presently has a consensus target price of $86.00, indicating a potential upside of 63.96%. Revolution Medicines has a consensus target price of $103.88, indicating a potential downside of 26.99%. Given Vaxcyte's higher possible upside, equities research analysts plainly believe Vaxcyte is more favorable than Revolution Medicines.

Vaxcyte's return on equity of -32.83% beat Revolution Medicines' return on equity.

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by insiders. Comparatively, 8.2% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Vaxcyte has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

In the previous week, Insmed had 16 more articles in the media than Vaxcyte. MarketBeat recorded 26 mentions for Insmed and 10 mentions for Vaxcyte. Insmed's average media sentiment score of 0.87 beat Vaxcyte's score of 0.46 indicating that Insmed is being referred to more favorably in the news media.

Vaxcyte has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Insmed has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500.

Vaxcyte presently has a consensus target price of $86.00, indicating a potential upside of 63.96%. Insmed has a consensus target price of $212.36, indicating a potential upside of 100.77%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Vaxcyte.

Vaxcyte has a net margin of 0.00% compared to Insmed's net margin of -210.54%. Vaxcyte's return on equity of -32.83% beat Insmed's return on equity.

96.8% of Vaxcyte shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, BioNTech had 16 more articles in the media than Vaxcyte. MarketBeat recorded 26 mentions for BioNTech and 10 mentions for Vaxcyte. BioNTech's average media sentiment score of 0.49 beat Vaxcyte's score of 0.46 indicating that BioNTech is being referred to more favorably in the media.

15.5% of BioNTech shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 3.1% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Vaxcyte has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

BioNTech has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.

BioNTech currently has a consensus target price of $131.60, indicating a potential upside of 38.59%. Vaxcyte has a consensus target price of $86.00, indicating a potential upside of 63.96%. Given Vaxcyte's higher probable upside, analysts plainly believe Vaxcyte is more favorable than BioNTech.

Vaxcyte has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Vaxcyte's return on equity.

In the previous week, Vaxcyte had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 10 mentions for Vaxcyte and 6 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.41 beat Vaxcyte's score of 0.46 indicating that Roivant Sciences is being referred to more favorably in the media.

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by company insiders. Comparatively, 3.1% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Roivant Sciences has higher revenue and earnings than Vaxcyte. Roivant Sciences is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Roivant Sciences has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.

Roivant Sciences currently has a consensus target price of $30.55, indicating a potential upside of 7.49%. Vaxcyte has a consensus target price of $86.00, indicating a potential upside of 63.96%. Given Vaxcyte's higher probable upside, analysts plainly believe Vaxcyte is more favorable than Roivant Sciences.

Vaxcyte has a net margin of 0.00% compared to Roivant Sciences' net margin of -6,079.94%. Roivant Sciences' return on equity of -19.04% beat Vaxcyte's return on equity.